Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/EP300_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/EP300_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/EP300_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/EP300_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/EP300_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/EP300_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003052121 | Liver | HCC | androgen receptor signaling pathway | 31/7958 | 44/18723 | 1.63e-04 | 1.30e-03 | 31 |
GO:0009411 | Liver | HCC | response to UV | 85/7958 | 149/18723 | 2.34e-04 | 1.77e-03 | 85 |
GO:00439231 | Liver | HCC | positive regulation by host of viral transcription | 14/7958 | 16/18723 | 2.73e-04 | 1.98e-03 | 14 |
GO:004851121 | Liver | HCC | rhythmic process | 156/7958 | 298/18723 | 3.54e-04 | 2.46e-03 | 156 |
GO:0098732 | Liver | HCC | macromolecule deacylation | 67/7958 | 116/18723 | 6.46e-04 | 3.99e-03 | 67 |
GO:00305111 | Liver | HCC | positive regulation of transforming growth factor beta receptor signaling pathway | 23/7958 | 32/18723 | 7.37e-04 | 4.47e-03 | 23 |
GO:19038461 | Liver | HCC | positive regulation of cellular response to transforming growth factor beta stimulus | 23/7958 | 32/18723 | 7.37e-04 | 4.47e-03 | 23 |
GO:00510902 | Liver | HCC | regulation of DNA-binding transcription factor activity | 220/7958 | 440/18723 | 8.04e-04 | 4.82e-03 | 220 |
GO:000863011 | Liver | HCC | intrinsic apoptotic signaling pathway in response to DNA damage | 58/7958 | 99/18723 | 8.97e-04 | 5.29e-03 | 58 |
GO:0040029 | Liver | HCC | regulation of gene expression, epigenetic | 61/7958 | 105/18723 | 9.02e-04 | 5.31e-03 | 61 |
GO:000717921 | Liver | HCC | transforming growth factor beta receptor signaling pathway | 106/7958 | 198/18723 | 1.09e-03 | 6.23e-03 | 106 |
GO:00356011 | Liver | HCC | protein deacylation | 64/7958 | 112/18723 | 1.23e-03 | 6.83e-03 | 64 |
GO:00106772 | Liver | HCC | negative regulation of cellular carbohydrate metabolic process | 28/7958 | 42/18723 | 1.35e-03 | 7.26e-03 | 28 |
GO:00454441 | Liver | HCC | fat cell differentiation | 120/7958 | 229/18723 | 1.52e-03 | 8.05e-03 | 120 |
GO:00061111 | Liver | HCC | regulation of gluconeogenesis | 31/7958 | 48/18723 | 1.66e-03 | 8.71e-03 | 31 |
GO:00459122 | Liver | HCC | negative regulation of carbohydrate metabolic process | 31/7958 | 48/18723 | 1.66e-03 | 8.71e-03 | 31 |
GO:001097511 | Liver | HCC | regulation of neuron projection development | 220/7958 | 445/18723 | 1.68e-03 | 8.78e-03 | 220 |
GO:00432551 | Liver | HCC | regulation of carbohydrate biosynthetic process | 56/7958 | 97/18723 | 1.75e-03 | 9.11e-03 | 56 |
GO:0010976 | Liver | HCC | positive regulation of neuron projection development | 88/7958 | 163/18723 | 1.98e-03 | 1.00e-02 | 88 |
GO:004277111 | Liver | HCC | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 28/7958 | 43/18723 | 2.30e-03 | 1.14e-02 | 28 |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
EP300 | BAS | Skin | SCCIS | AC104365.1,STX18-AS1,VASN, etc. | 1.89e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Skin/Str/TF_SCCIS/regulons_activity_in_dotplot.png) |
EP300 | STM | Thyroid | ADJ | AL096865.1,MACF1,DDX17, etc. | 5.60e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Thyroid/Str/TF_ADJ/regulons_activity_in_dotplot.png) |
EP300 | STM | Thyroid | PTC | AL096865.1,MACF1,DDX17, etc. | 4.33e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Thyroid/Str/TF_PTC/regulons_activity_in_dotplot.png) |
EP300 | CD4TN | Thyroid | ADJ | SECISBP2L,NKRF,SYNE2, etc. | 3.30e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Thyroid/Str/TF_ADJ/regulons_activity_in_dotplot.png) |
EP300 | CD4TN | Thyroid | ATC | SECISBP2L,NKRF,SYNE2, etc. | 1.17e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Thyroid/Str/TF_ATC/regulons_activity_in_dotplot.png) |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EP300 | SNV | Missense_Mutation | | c.5528A>C | p.Gln1843Pro | p.Q1843P | Q09472 | protein_coding | tolerated(1) | benign(0.003) | TCGA-A2-A0T5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Taxotere | SD |
EP300 | SNV | Missense_Mutation | | c.6023N>T | p.Ser2008Phe | p.S2008F | Q09472 | protein_coding | tolerated(0.06) | benign(0.203) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
EP300 | SNV | Missense_Mutation | rs769721803 | c.1349N>T | p.Ala450Val | p.A450V | Q09472 | protein_coding | tolerated(0.07) | possibly_damaging(0.771) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
EP300 | SNV | Missense_Mutation | rs775556373 | c.5854N>G | p.Ile1952Val | p.I1952V | Q09472 | protein_coding | tolerated(0.33) | benign(0) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EP300 | SNV | Missense_Mutation | | c.4352N>C | p.His1451Pro | p.H1451P | Q09472 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C8-A27B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
EP300 | SNV | Missense_Mutation | | c.4608A>T | p.Glu1536Asp | p.E1536D | Q09472 | protein_coding | tolerated(0.07) | probably_damaging(0.994) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
EP300 | SNV | Missense_Mutation | | c.2498N>T | p.Ser833Leu | p.S833L | Q09472 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.992) | TCGA-D8-A1XM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EP300 | SNV | Missense_Mutation | | c.980C>T | p.Ala327Val | p.A327V | Q09472 | protein_coding | tolerated(0.08) | possibly_damaging(0.833) | TCGA-D8-A1XZ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen+anastrozolum | SD |
EP300 | SNV | Missense_Mutation | novel | c.2744G>T | p.Arg915Leu | p.R915L | Q09472 | protein_coding | tolerated_low_confidence(0.64) | benign(0) | TCGA-E2-A1LK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
EP300 | SNV | Missense_Mutation | novel | c.1440N>A | p.Met480Ile | p.M480I | Q09472 | protein_coding | tolerated(0.54) | benign(0.076) | TCGA-EW-A423-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 178103579 | CURCUMIN | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 178103614 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | | DIETHYL-2-UNDECYLIDENEMALONATE | CHEMBL1797707 | 21292492 |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 187051830 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 249565916 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | | DIETHYL-2-PENTADECYLIDENEMALONATE | CHEMBL404916 | 21292492 |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 178103615 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | | DIETHYL-2-TETRADECYLIDENEMALONATE | CHEMBL257748 | 21292492 |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 178103578 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | | DIETHYL-2-DODECYLIDENEMALONATE | CHEMBL1797708 | 21292492 |